12663707

Source:http://linkedlifedata.com/resource/pubmed/id/12663707

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0007134, umls-concept:C0008976, umls-concept:C0021747, umls-concept:C0087111, umls-concept:C0282461, umls-concept:C1512162, umls-concept:C1514888, umls-concept:C1522673
pubmed:issue	7
pubmed:dateCreated	2003-3-28
pubmed:abstractText	To evaluate the role of adjuvant interferon alfa after complete resection of locally extensive renal cell carcinoma.
pubmed:grant	http://linkedlifedata.com/resource/pubmed/grant/CA-23318
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/12663707-12663704
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/8309333
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Interferon-alpha
pubmed:status	MEDLINE
pubmed:month	Apr
pubmed:issn	0732-183X
pubmed:author	pubmed-author:CrawfordE DavidED, pubmed-author:Eastern Cooperative Oncology Group/Intergroup trial, pubmed-author:FleischmannJonathanJ, pubmed-author:HahnRichardR, pubmed-author:ManolaJudithJ, pubmed-author:MessingEdward MEM, pubmed-author:PontesJ EdsonJE, pubmed-author:PropertKathleenK, pubmed-author:TrumpDonaldD, pubmed-author:WildingGeorgeG
pubmed:issnType	Print
pubmed:day	1
pubmed:volume	21
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	1214-22
pubmed:dateRevised	2007-11-14
pubmed:meshHeading	pubmed-meshheading:12663707-Adult, pubmed-meshheading:12663707-Aged, pubmed-meshheading:12663707-Carcinoma, Renal Cell, pubmed-meshheading:12663707-Chemotherapy, Adjuvant, pubmed-meshheading:12663707-Combined Modality Therapy, pubmed-meshheading:12663707-Disease-Free Survival, pubmed-meshheading:12663707-Drug Administration Schedule, pubmed-meshheading:12663707-Female, pubmed-meshheading:12663707-Follow-Up Studies, pubmed-meshheading:12663707-Humans, pubmed-meshheading:12663707-Interferon-alpha, pubmed-meshheading:12663707-Kidney Neoplasms, pubmed-meshheading:12663707-Lymph Node Excision, pubmed-meshheading:12663707-Male, pubmed-meshheading:12663707-Middle Aged, pubmed-meshheading:12663707-Neoplasm Recurrence, Local, pubmed-meshheading:12663707-Nephrectomy, pubmed-meshheading:12663707-Prognosis, pubmed-meshheading:12663707-Survival Rate, pubmed-meshheading:12663707-Treatment Outcome
pubmed:year	2003
pubmed:articleTitle	Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial.
pubmed:affiliation	University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA. edward_messing@urmc.rochester.edu
pubmed:publicationType	Journal Article, Clinical Trial, Research Support, U.S. Gov't, P.H.S., Randomized Controlled Trial, Clinical Trial, Phase III